



## Resolution n°24-2024-e

### **Cost Extension for the Project “Integrating PrEP into Comprehensive Services for Adolescent Girls and Young Women”**

Recalling Unitaid Board Resolution R21-2017-e in which the Board authorized the Executive Director to commit up to US\$ 10,662,674 for the project entitled “*Integrating PrEP into Comprehensive Services for Adolescent Girls and Young Women*” (the “Project”), to be implemented by Wits Health Consortium (Pty) Ltd on behalf of Wits Reproductive Health and HIV Institute (“Wits RHI”) for a 3-year period;

Noting that in 2020 and 2021, the Secretariat approved two no-cost extensions to the duration of funding for the Project of 9 and 3 months respectively, together ending on 31 December 2021;

Recalling Resolution R27-2021-e, in which the Board approved additional funding of up to US\$ 9,861,380 for the expansion of PrEP options within the Project activities, and extended the duration of funding for the Project by 3 years to 31 December 2024;

Recalling Resolution R2-2024-e, in which the Board approved additional funding of up to US\$ 15,000,000 for the implementation of market shaping interventions under a new output (Output 4), and extended the duration of funding for Output 4 to 31 December 2026;

Noting the opportunity to now also leverage the Project to rapidly accelerate access to lenacapavir; and acknowledging the market-shaping interventions that are already in place in the PrEP portfolio to accelerate access to generic lenacapavir at the lowest possible cost, as well as Unitaid’s other investments that support expanded access, and the opportunity to complement such investments with activities to lay the foundations for rapid country introduction and uptake of lenacapavir; and

Taking into account the assessment by the PRC and the Secretariat’s recommendations with respect to the Project extension proposal submitted by Wits RHI, the Board authorizes the Executive Director, subject to the availability of funds, to commit additional funding of up to US\$ 16,046,486 for the Project (up to US\$ 8,158,515 for Outputs 1-3 and up to US\$ 7,887,971 for Output 4), and to extend the duration of funding for Outputs 1-3 by 36 months and for Output 4 by 12 months, up to 31 December 2027 for all Outputs.

The additional funding and extension is conditional upon signature of a formal amendment to the grant agreement for the Project.

Marisol Touraine  
Chair of the Executive Board

Date: 1 December 2024

A handwritten signature in blue ink that reads "Marisol Touraine". Below the signature is a horizontal line.